Cyclooxygenase-2 in cervical neoplasia: A review

Gynecologic Oncology

Volumn 109, Issue 1, 2008, Pages 140-145

  Young, Jennifer L ^a   Jazaeri, Amir A ^a   Darus, Christopher J ^b   Modesitt, Susan C ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b MAINE MEDICAL CENTER   (United States)

Author keywords

Celecoxib; Cervical cancer; Cervical intraepithelial neoplasia; Cyclooxygenase 2; Inflammation

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; INDOMETACIN; PLACEBO; ROFECOXIB; SULINDAC;

ANGIOGENESIS; ANKYLOSING SPONDYLITIS; BRAIN METASTASIS; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CARDIOVASCULAR DISEASE; CAUTERIZATION; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CORRELATIONAL STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ESOPHAGUS CANCER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; INFLAMMATION; LUNG NON SMALL CELL CANCER; OSTEOARTHRITIS; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; UTERINE CERVICAL NEOPLASMS;

EID: 40949114530     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.01.008     Document Type: Review

References (55)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Stat bite: worldwide cervical and uterine cancer incidence and mortality, 2002. J Natl Cancer Inst 98 (2006) 1031
3. Frazer I.H., Cox J.T., Mayeaux Jr. E.J., Franco E.L., Moscicki A.B., Palefsky J.M., et al. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediatr Infect Dis J 25 (2006) S65-S81
4. Baseman J.G., and Koutsky L.A. The epidemiology of human papillomavirus infections. J Clin Virol 32 Suppl 1 (2005) S16-S24
5. Jones B., and Davey D. Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med 124 (2000) 672-681
6. Castle P.E., and Giuliano A.R. Chapter 4: genital tract infections, cervical inflammation, and antioxidant nutrients-assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst (2003) 29-34 Monographs
7. Moss S.F., and Blaser M.J. Mechanisms of disease: inflammation and the origins of cancer. Nat Clin Pract Oncol 2 (2005) 90-97 quiz 1 p following 113
8. McIntyre-Seltman K., Castle P.E., Guido R., Schiffman M., Wheeler C.M., and Group A. Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. Cancer Epidemiol Biomarkers Prev 14 (2005) 1165-1170
9. Castle P.E., Hillier S.L., Rabe L.K., Hildesheim A., Herrero R., Bratti M.C., et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev 10 (2001) 1021-1027
10. Vane J., Bakhe Y., and Botting R. Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol 38 (1998) 97-120
11. Dai Y., Zhang X., Peng Y., and Wang Z. The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma. Gynecol Oncol 97 (2005) 96-103
12. Dannenberg A.J., Lippman S.M., Mann J.R., Subbaramaiah K., and DuBois R.N. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23 (2005) 254-266
13. Subbaramaiah K., and Dannenberg A.J. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange. Cancer Res 67 (2007) 3976-3985
14. Zijlmans H.J.M.A.A., Fleuren G.J., Baelde H.J., Eilers P.H.C., Kenter G.G., and Gorter A. Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma. Cancer 109 (2007) 556-565
15. Nair A., Venkatraman M., Maliekal T.T., Nair B., and Karunagaran D. NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 22 (2003) 50-58
16. Pandey M., Bajaj G.D., and Rath P.C. Induction of the interferon-inducible RNA-degrading enzyme, RNase L, by stress-inducing agents in the human cervical carcinoma cells. RNA Biology 1 (2004) 21-27
17. Branca M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S., et al. Upregulation of nuclear factor-kappaB (NF-kappaB) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus or disease outcome in cervical cancer. Diagn Cytopathol 34 (2006) 555-563
18. Weinberg R. The biology of cancer. New York, NY: Garland Science, Taylor Francis Group, LLC; 2007.
19. Cha Y.I., and DuBois R.N. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 58 (2007) 239-252
20. Mori H., Hanabayashi T., Yamada Y., and Tamaya T. Decrease in interferon-gamma production by peripheral blood mononuclear cells in patients with uterine cervical cancer. J Clin Immunol 10 (1990) 45-51
21. Ohshika Y., Umesaki N., and Sugawa T. Immunomodulating capacity of the monocyte-macrophage system in patients with uterine cervical cancer. Nippon Sanka Fujinka Gakkai Zasshi - Acta Obstetrica et Gynaecologica Japonica 40 (1988) 601-608
22. Kim M.H., Seo S.S., Song Y.S., Kang D.H., Park I.A., Kang S.B., et al. Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes. Gynecol Oncol 90 (2003) 83-90
23. Ferrandina G., Lauriola L., Distefano M.G., Zannoni G.F., Gessi M., Legge F., et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 20 (2002) 973-981
24. Govindan R., McLeod H., Mantravadi P., Fineberg N., Helft P., Kesler K., et al. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology (Huntington) 18 (2004) 18-21
25. Kim H.J., Wu H.G., Park I.A., and Ha S.W. High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 55 (2003) 16-20
26. Lindstrom A.K., Stendahl U., Tot T., Lidstrom B.M., and Hellberg D. Predicting the outcome of squamous cell carcinoma of the uterine cervix using combinations of individual tumor marker expressions. Anticancer Res 27 (2007) 1609-1615
27. Kim G.E., Kim Y.B., Cho N.H., Chung H.C., Pyo H.R., Lee J.D., et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res 10 (2004) 1366-1374
28. Shi X., Chen G., Xing H., Weng D., Bai X., and Ma D. VEGF-C, VEGFR-3, and COX-2 enhances growth and metastasis of human cervical carcinoma cell lines in vitro. Oncol Rep 18 (2007) 241-247
29. Lancaster J., Cooper R.A., Logue J.P., Davidson S.E., Hunter R.D., and West C.M.L. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 83 (2000) 620-625
30. Guo P.T. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem Biophys Res Commun 299 (2002) 886-890
31. Gallo O., Franchi A., Magnelli L., Sardi I., Vannacci A., Boddi V., et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia (New York) 3 (2001) 53-61
32. Kim K.Y., Seol J.Y., Jeon G.A., and Nam M.J. The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 and caspase-3 in human cervical cancer cell. Cancer Lett 189 (2003) 157-166
33. Kim S.H., Song S.H., Kim S.G., Chun K.S., Lim S.Y., Na H.K., et al. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol 130 (2004) 551-560
34. Raju U., Ariga H., Dittmann K., Nakata E., Ang K.K., and Milas L. Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. Int J Radiat Oncol Biol Phys 63 (2005) 520-528
35. Nakata E., Mason K.A., Hunter N., Husain A., Raju U., Liao Z., et al. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys 58 (2004) 369-375
36. Raju U., Nakata E., Yang P., Newman R.A., Ang K.K., and Milas L. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys 54 (2002) 886-894
37. Hashitani S., Urade M., Nishimura N., Maeda T., Takaoka K., Noguchi K., et al. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol 23 (2003) 665-672
38. Kwak Y.E., Jeon N.K., Kim J., and Lee E.J. The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma. Ann N Y Acad Sci 1095 (2007) 99-112
39. Liao Z., Komaki R., Milas L., Yuan C., Kies M., Chang J.Y., et al. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 11 (2005) 3342-3348
40. Cerchietti L.C.A., Bonomi M.R., Navigante A.H., Castro M.A., Cabalar M.E., and Roth B.M.C. Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. J Neurooncol 71 (2005) 73-81
41. Blanke C.D., Mattek N.C., Deloughery T.G., and Koop D.R. A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer. Prostaglandins Other Lipid Mediat 75 (2005) 169-172
42. Pan C.X., Loehrer P., Seitz D., Helft P., Juliar B., Ansari R., et al. A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. Oncology 69 (2005) 63-70
43. Ferrandina G., Ranelletti F.O., Legge F., Lauriola L., Salutari V., Gessi M., et al. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clin Cancer Res 9 (2003) 4324-4331
44. Herrera F.G., Chan P., Doll C., Milosevic M., Oza A., Syed A., et al. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys 67 (2007) 97-103
45. Gaffney D.K., Winter K., Dicker A.P., Miller B., Eifel P.J., Ryu J., et al. A phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys 67 (2007) 104-109
46. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
47. Solomon S.D., Pfeffer M.A., McMurray J.J.V., Fowler R., Finn P., Levin B., et al., Investigators APCaPT. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114 (2006) 1028-1035
48. Matchaba P., Gitton X., Krammer G., Ehrsam E., Sloan V.S., Olson M., et al. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clin Ther 27 (2005) 1196-1214
49. White W.B., West C.R., Borer J.S., Gorelick P.B., Lavange L., Pan S.X., et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 99 (2007) 91-98
50. Farley J., Uyehara C., Hashiro G., Belnap C., Birrer M., and Salminen E. Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure. Gynecol Oncol 92 (2004) 596-602
51. Powell MPJ, Buttin BB, Gibb RK, Luck MD, Rader JS. A pilot study of celecoxib in the treatment of patients with cervical and vaginal intraepithelial neoplasia. In: American Society of Clinical Oncology; 2003. p. Abstract 1830.
52. Hefler L.A., Grimm C., Speiser P., Sliutz G., and Reinthaller A. The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III a phase II trial. Eur J Obstet Gynecol Reprod Biol 125 (2006) 251-254
53. Farley J.H., Truong V., Goo E., Uyehara C., Belnap C., and Larsen W.I. A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia. Gynecol Oncol 103 (2006) 425-430
54. Rader J., Muller C., and Trimble C. A randomized double-blind phase II trial of celecoxib, a COX-2 inhibitor, in the treatment of patients with cervical intraepithelial neoplasia 3 (CIN3). Protocol GOG-0207 (2005), Gynecologic Oncology Group, Philadelphia, PA
55. Kyrgiou M., Koliopoilos G., Martin-Hirsch P., Arbyn M., Prendiville W., and Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. The Lancet (2006) 367